Beyond Air announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026. This figure represents a 30% sequential increase from the prior quarter and a 27% year-over-year growth, marking the highest quarterly revenue reported to date. The company reaffirmed its previously issued revenue guidance of $8 million for calendar year 2026 and $16 million to $18 million for calendar year 2027. Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on harnessing nitric oxide technology to treat respiratory illnesses.
